Nucala (mepolizumab) Coverage Criteria
Customize your policy alerts
Sign up for all goldcoasthealthplan policy alerts
Know when goldcoasthealthplan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs Part B prior authorization and coverage criteria for Nucala (mepolizumab) for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. It applies to providers requesting initial coverage or reauthorization for eligible members.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.